2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读

doi:10.16150/j.1671-2870.2017.05.001

摘要/Abstract

中图分类号:

R551.3

侯健, 刘进. 2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读[J]. 诊断学理论与实践, 2017, 16(05): 455-459.

[1] Rajkumar SV, Larson D, Kyle RA.Diagnosis of smoldering multiple myeloma[J]. N Engl J Med,2011,365(5):474-475.
[2] Kastritis E, Terpos E, Moulopoulos L, et al.Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease[J]. Leukemia,2013,27(4):947-953.
[3] Waxman AJ, Mick R, Garfall AL, et al.Modeling the risk of progression in smoldering multiple myeloma[J]. J Clin Oncol,2014,32(5s):A8607.
[4] Larsen JT, Kumar SK, Dispenzieri A, et al.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma[J]. Leukemia,2013,27(4):941-946.
[5] Hillengass J, Fechtner K, Weber MA, et al.Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma[J]. J Clin Oncol,2010,28(9):1606-1610.
[6] Kastritis E, Moulopoulos LA, Terpos E, et al.The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma[J]. Leukemia,2014,28(12):2402-2403.
[7] Palumbo A, Avet-Loiseau H, Oliva S, et al.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group[J]. J Clin Oncol,2015,33(26):2863-2869.
[8] Palumbo A, Bringhen S, Mateos MV, et al.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report[J]. Blood,2015,125(13):2068-2074.
[9] Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2017,28(suppl_4):iv52-iv61.
[10] Palumbo A, Hajek R, Delforge M, et al.Continuous lenalidomide treatment for newly diagnosed multiple myeloma[J]. N Engl J Med,2012,366(19):1759-1769.
[11] Attal M, Palumbo A, Holstein SA, et al.Lenalidomide maintenance after high-dose melphalan and autologous stem-cell transplantation in multiple myeloma: a meta-analysis of overall survival[J]. J Clin Oncol,2016,34(Suppl):8001.
[12] Laubach J, Garderet L, Mahindra A, et al.Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group[J]. Leukemia,2016, 30(5):1005-1017.
[13] Stewart AK, Rajkumar SV, Dimopoulos MA, et al.Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma[J]. N Engl J Med,2015,372(2):142-152.
[14] Dimopoulos MA, Moreau P, Palumbo A, et al.Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study[J]. Lancet Oncol,2016,17(1):27-38.
[15] Lonial S, Dimopoulos M, Palumbo A, et al.Elotuzumab therapy for relapsed or refractory multiple myeloma[J]. N Engl J Med,2015,373(7):621-631.
[16] Moreau P, Masszi T, Grzasko N, et al.Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med,2016,374(17):1621-1634.
[17] San-Miguel JF, Hungria VT, Yoon SS, et al.Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial[J]. Lancet Oncol,2014,15(11):1195-1206.
[18] San Miguel J, Weisel K, Moreau P, et al.Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial[J]. Lancet Oncol,2013,14(11):1055-1066.
[19] Usmani SZ, Weiss BM, Plesner T, et al.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma[J]. Blood,2016,128(1):37-44.
[20] Palumbo A, Chanan-Khan A, Weisel K, et al.Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma[J]. N Engl J Med,2016,375(8):754-766.
[21] Dimopoulos MA, Oriol A, Nahi H, et al.Daratumumab, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med,2016,375(14):1319-1331.

2017年欧洲肿瘤内科学会多发性骨髓瘤的指南更新解读

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚. LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605.
[2]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[3]	沈银忠. 《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.
[4]	施霞, 马鑫, 王珍燕, 张晖, 刘少军. 32例人类免疫缺陷病毒感染合并慢性肾病患者的临床病理特征及随访结果分析[J]. 诊断学理论与实践, 2022, 21(04): 437-443.
[5]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[6]	何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[7]	徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊. 实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550.
[8]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[9]	赵然, 詹维伟, 侯怡卿. 计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394.
[10]	郭业兵, 郑金峰. 阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407.
[11]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 133-135.
[12]	王刚, 陈生弟. 神经病学的诊断：起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4.
[13]	唐静仪, 余群, 刘军. 结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17.
[14]	魏文石. 直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7.
[15]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.